Ipca Labs shareholders approve re-appointment of Pranay Godha as MD
Mumbai: Through a recent BSE filing, Ipca Labs has informed that the shareholders of the company at the 73rd Annual General Meeting held have approved the re-appointment of Pranay Godha as the Managing Director of the Company with effect from 11th November, 2023 for the period of five years till 10th November, 2028.
Pranay Godha, aged 51 years has done his B.Sc. from University of Bombay and has also obtained a degree in MBA from the New York Institute of Technology, USA. He has nearly 2 decades of experience, inter-alia, in the field of Research, production, quality, Marketing and General Management.
Pranay Godha was appointed as the Business Development Manager of the Company w.e.f 16th April, 2003 and was subsequently promoted as Vice President - Generics Business of the Company w.e.f. 1st November, 2004. He was further promoted as President - Generics Business of the Company in May, 2006 and subsequently appointed as the Executive Director of the Company with effect from 11th November, 2008 and as Managing Director w.e.f 1st April, 2023.
Read also: Ipca Labs buys 33.38 percent stake in Unichem for over Rs 945 crore
Ipca Laboratories Limited is an Indian multinational pharmaceutical company headquartered in Mumbai. The Company was founded by group of businessmen and medical professionals in 1949. It produces theobromine, acetyl thiophene, and p-bromotoluene as active pharmaceutical ingredients (APIs). Ipca sells these APIs and their intermediates globally. Ipca is a fully-integrated pharmaceutical company that manufactures over 350 formulations and 80 APIs for various therapeutic segments.
Read also: IPCA Lab gets CDSCO panel nod for phase 3 trial of HCQ as add-on therapy in type 2 diabetes
